TH1901 / Theratechnologies - LARVOL DELTA

[VIRTUAL] TH1901, a novel curcumin-peptide conjugate for the treatment of Sortilin-positive (SORT1+) cancer (AACR-II 2020) - "Interestingly, conjugation of curcumin also increased its in vitro stability in solution. In vivo, intraperitoneal administration of TH1901 (60 mg/kg/twice a week) inhibited growth of SORT1+ HT-29 colorectal cancer cell subcutaneous xenograft tumors, whereas at an equivalent dose unconjugated curcumin (15 mg/kg/twice a week) had no effect.Conclusion : Overall, these proof-of-concept experiments support the future development of this flexible and innovative platform to generate novel anticancer treatments."

Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • SORT1 • TNFA